Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Relish the World: Notable Caf\u00e9s You Really want to Attempt - 2Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- 3Sexual violence part of 'everyday life' in parts of Sudan, charity says
- 4'All's Fair,' Ryan Murphy's new show starring Kim Kardashian, hit with scathing reviews: 'A girlboss fever dream'
- 521 Incredibly Interesting Contemplations To Observe Consistently
- Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- Infants will no longer receive hepatitis B vaccine at birth, CDC announces
- Striking American and European television Projects: A Survey
- What's the Fate of 5G Innovation?
- Old food pyramid vs. RFK Jr.'s new food pyramid. See what's different.
- Students were skipping my astrophysics class to play video games – so I turned the class itself into a video game
- Iran denies launching ballistic missiles towards Kurdistan region of Iraq
- The Solution to Flexibility: Developing Internal Fortitude Notwithstanding Misfortune
- Which European countries have mandatory or voluntary military service
